Psoriasis flare drug study pulled before it began

NCT ID NCT06886009

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It was a regulatory requirement to monitor real-world use after the drug's launch in Korea.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Spesolimab (Spevigo®)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Pusan National University Yangsan Hospital

    Busan, 49241, South Korea

  • Samsung Medical Center

    Seoul, 06351, South Korea